Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Part of paid clinical trials in San Antonio, Texas.

Sponsor
Plus Therapeutics
Study ID
NCT07098806
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Leptomeningeal Metastasis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 186RNL — DRUG
    Multiple Doses of 186RNL

Study Details

This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases to identify an MTD/MFD for a given dose, interval duration, and number of doses.

Key Dates

Start date
Jul 2, 2025
Status verified
Jul 2025
Primary completion
Oct 2, 2026
Completion
Oct 2, 2031

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental: Multiple Doses
    This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases to identify an MTD/MFD for a given dose, interval duration, and number of doses.

Primary Outcome Measure

Maximum Tolerated Dose [ Time Frame: 13 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The Cancer Therapy and Research Center at UTHSCSASan AntonioTexas78229
Leti Velten, RN
[email protected]
210-450-1921
Andrew Brenner, M.D.,Ph.D (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Antonio, TX

By research site
The Cancer Therapy and Research Center at UTHSCSA· San Antonio, TX

Related Studies